Eagle's Eye View: Your Weekly CV Update From ACC.org

American College of Cardiology
  • 4.8（120則評分）
  • 醫學
  • 每日更新
Eagle's Eye View: Your Weekly CV Update From ACC.org

The weekly cardiovascular update from ACC.org Editor-in-Chief Kim Eagle, MD, MACC, covering the hottest cardiovascular topics, from new clinical guidelines to practice-changing research and innovative quality initiatives and tools.

  1. 2 天前

    Discontinuing Drug Treatment in HFrEF, Race and Sacubitril/Valsartan Use in HF, Systolic BP Polygenic Risk Score Treatment Responses

    In this week’s View, Dr. Eagle looks at the consequences of discontinuing long-term drug treatment in patients with heart failure and reduced ejection fraction (HFrEF). He then explores the effect of race and sacubitril/valsartan use in HF patients documented in a pooled analysis of the PARADIGM-HF and PARAGON-HF trials. Finally, Dr. Eagle discusses the utility of systolic blood pressure (BP) polygenic risk scores and the treatment response in people with hypertension.    Subscribe to Eagle’s Eye View

    9 分鐘

  2. 10月23日

    Anthracycline Cardiotoxicity in Cancer Patients; Arrhythmias, Autonomic Dysfunction and COVID-19; Lowering Non–HDL Cholesterol After MI

    In this week’s View, Dr. Eagle looks at anthracycline cardiotoxicity in treatment of cancer patients. He then explores a scientific statement from the American Heart Association on cardiac arrhythmias and autonomic dysfunction associated with COVID-19. Finally, Dr. Eagle discusses the SWEDEHEART registry and intensive early and sustained lowering of non–HDL cholesterol after MI and prognosis.    Subscribe to Eagle’s Eye View

    9 分鐘

  3. 10月16日

    Semaglutide and BP, HF Risk Assessment Using Biomarkers, DAPT After Drug-Eluting Stenting in ACS

    In this week’s View, Dr. Eagle looks at an individual patient data meta-analysis of semaglutide and blood pressure (BP). He then explores an analysis from COMBINE-AF on heart failure (HF) risk assessment using biomarkers in patients with atrial fibrillation. Finally, Dr. Eagle discusses short-term dual antiplatelet therapy (DAPT) after drug-eluting stenting in patients with acute coronary syndrome (ACS).  Subscribe to Eagle’s Eye View

    10 分鐘

  4. 10月9日

    CV Events After COVID Vaccine, Septal Reduction in Obstructive HCM, Acute Pulmonary Embolism Guideline Comparison

    In this week’s View, Dr. Eagle looks at cardiovascular events following COVID vaccination in adults. He then explores long-term outcomes after septal reduction therapies in obstructive hypertrophic cardiomyopathy (HCM). Finally, Dr. Eagle discusses clinical practice guideline recommendations for acute pulmonary embolism.   Subscribe to Eagle’s Eye View

    11 分鐘

  5. 10月2日

    Hospital Survival After AAA Repair, Myocardial Fibrosis and Aortic Stenosis, MRA Use in HF

    In this week’s View, Dr. Eagle looks at sex-specific differences in alive hospital discharge following abdominal aortic aneurysm (AAA) repair. He then explores how diffuse interstitial fibrosis of the myocardium predicts outcomes in moderate and asymptomatic severe aortic stenosis. Finally, Dr. Eagle discusses the value of mineralocorticoid receptor antagonists (MRAs) in heart failure (HF).    Subscribe to Eagle’s Eye View

    8 分鐘

  6. 9月25日

    Risk Stratification in Nonischemic Dilated Cardiomyopathy, 2024 Guideline for Perioperative CV Management for Noncardiac Surgery, Lipoprotein(a) and Cardiovascular Disease

    In this week’s View, Dr. Eagle looks at risk stratification in nonischemic dilated cardiomyopathy using CMR imaging. He then discusses the recent update of the Guideline for Perioperative CV Management for Noncardiac Surgery. Finally, Dr. Eagle talks about a review article on lipoprotein(a) and CVD.   Subscribe to Eagle’s Eye View

    9 分鐘

  7. 9月18日

    Long-Term Outcomes in Pericarditis, Polygenic Risk Score and Predicting CVD, Aortic Disease in Children with FBN1-Related Marfan Syndrome

    In this week’s View, Dr. Eagle looks at predicting long-term outcomes in patients with recurrent pericarditis. He then explores how the polygenic risk score may add to the clinical risk estimate for predicting cardiovascular disease in populations. Finally, Dr. Eagle discusses the management of aortic disease in children with FBN1-related Marfan syndrome.   Subscribe to Eagle’s Eye View

    11 分鐘

  8. 9月12日

    Eight Practice-Changing Trials Featured at ESC Congress 2024

    In this special edition of Eagle’s Eye View, Dr. Eagle summarizes the most important trials that were featured at the ESC Congress 2024, August 30 to September 2—eight trials that could have significant influence on your day-to-day practice. They include: FINEARTS-HF, exploring the benefits of finerenone in patients with HFmrEF or HFpEF; SCOFF, asking if fasting prior to cath lab procedures is necessary; SENIOR-RITA on CV management in frail adults; SHAM-PVI, exploring pulmonary vein isolation vs. sham intervention in patients with asymptomatic AFib; ASSURE DES, examining continuing vs. interruptive aspirin therapy before noncardiac surgery in patients with DES; Stop-or-Not, on the continuation vs. discontinuation of RASIs prior to major noncardiac surgery; ABYSS, exploring the impact of interrupting or continuing beta-blocker treatment in patients with a history of MI; and  RESHAPE-HF2, on the impact of M-TEER on patients with FMR and symptomatic HF.   Subscribe to Eagle’s Eye View

    11 分鐘
顯示全部 (99)

4.8
（滿分 5 顆星）
120 則評分

簡介

The weekly cardiovascular update from ACC.org Editor-in-Chief Kim Eagle, MD, MACC, covering the hottest cardiovascular topics, from new clinical guidelines to practice-changing research and innovative quality initiatives and tools.

資訊

你可能也會喜歡

若要收聽兒少不宜的單集，請登入帳號。

隨時掌握此節目最新消息

登入或註冊後，即可追蹤節目、儲存單集和掌握最新資訊。
選取國家或地區

非洲、中東和印度

亞太地區

歐洲

拉丁美洲與加勒比海地區

美國與加拿大